Economic Spectroscopic Evaluation of Cervical Cancer

Information

  • Research Project
  • 8133463
  • ApplicationId
    8133463
  • Core Project Number
    R44CA110149
  • Full Project Number
    5R44CA110149-05
  • Serial Number
    110149
  • FOA Number
    RFA-CA-08-021
  • Sub Project Id
  • Project Start Date
    8/18/2004 - 20 years ago
  • Project End Date
    8/31/2014 - 10 years ago
  • Program Officer Name
    WEBER, PATRICIA A
  • Budget Start Date
    9/1/2011 - 13 years ago
  • Budget End Date
    8/31/2014 - 10 years ago
  • Fiscal Year
    2011
  • Support Year
    5
  • Suffix
  • Award Notice Date
    8/23/2011 - 13 years ago

Economic Spectroscopic Evaluation of Cervical Cancer

DESCRIPTION (provided by applicant): Guided Therapeutics has developed the LightTouch(R), a non invasive, point of care device that uses a combination of fluorescence and reflectance spectroscopy to measure the entire ecto-cervix in an imaging format. Our test is intended for use prior to colposcopy by a trained healthcare professional (e.g., physician, nurse practitioner, physician's assistant) to triage women found to have an intermediate Pap result to identify those women who have high grade disease. It could also be used to triage young women in whom HPV testing is not beneficial and where HPV infection rates may be as high as 80% regardless of whether dysplasia is present. In addition to identifying high grade disease, the LightTouch device can provide enhanced imaging that could help locate the disease on the cervix for guided biopsy and for treatment. We are applying for a Bridge Award in order to complete the final work required to bring LightTouch(R) through the FDA approval process, and begin production of a commercial device which incorporates the spectroscopic based cancer diagnostic system with high-definition imaging and mapping technologies to aid the physician in image-guided therapy. PUBLIC HEALTH RELEVANCE: LightTouch is a light-based, non-invasive and point-of-care technology that can be used to detect high grade cervical cancer in women. New guidelines issued by the American Society for Colposcopists and Cervical Pathologists (ASCCP) to categorize the likelihood of a woman having cancer indicate a need for new technology to detect high grade dysplasia (cancer), especially in younger women, women with positive HPV test results, and women with Pap smear results of ASC (Atypical Squamous Cells) as part of a more effective triage strategy. LightTouch can identify the actual existence of high grade dysplasia thereby shortening the time for treatment and follow-up for healthy women, increasing screening effectiveness, and pre-selecting those patients that need to be seen by a colposcopist more urgently for the treatment of dysplasia.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    517125
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:517125\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GUIDED THERAPEUTICS
  • Organization Department
  • Organization DUNS
    800743106
  • Organization City
    NORCROSS
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    300923413
  • Organization District
    UNITED STATES